Daratumumab Improves Progression-Free Survival for Patients with Multiple Myeloma
A summary of clinical trial results showing that daratumumab plus lenalidomide and dexamethasone improved progression-free survival for patients with relapsed or refractory disease.
Media Type: Html
- SourceUrl: https://www.cancer.gov/node/1070678/syndication
- Syndication ID: 16474
- Language: English
- Source: National Cancer Institute (NCI)
- Date Syndication Captured: Thursday, January 05, 2017 at 12:10 AM
- Date Syndication Updated: Monday, August 05, 2019 at 07:40 PM
Embed Code Snippet
To get the embed code snippet please Login.
